Wedbush Securities initiated coverage on Regulus Therapeutics RGLS with an Outperform rating and a $10 price target.
Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."
Regulus Therapeutics closed at $4.34 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in